Alkermes Brushes Off IP Pressures To Look to Potential Blockbuster Vivitrol
Executive Summary
Recent intellectual property rulings have potentially been both positive and negative for specialty company Alkermes, which is still forecasting growing revenues driven by its marketed opioid addiction therapy and progress with its Phase III CNS products pipeline.
You may also be interested in...
Finance Watch: Second Quarter Begins With Solid Base For Biopharma VC, Shaky Ground For Acorda
First quarter VC investments in biopharma set high expectations for the second quarter; Acorda cuts jobs after patent litigation defeat, plus other strategic realignments; no new US IPOs, but Europe has three; and notable follow-on offerings.
Ampyra, Patents, And The Perils Of Letting PTAB Get Your Hopes Up
In an unusual twist, district court ruled Acorda patents invalid after company defeated Kyle Bass' inter partes review challenge; Bass has won 10 IPR decisions, lost 9 and has one pending.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.